Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone

A Randomised, Single Blind, Multicentre, 9-month, Phase IV Study, Comparing Treatment Guided by Clinical Symptoms and Signs and NT-proBNP vs Treatment Guided by Clinical Symptoms and Signs Alone, in Patients With Heart Failure (HF) and Left Ventricular Systolic Dysfunction

The purpose is to study if HF treatment guided by NTproBNP in addition to clinical symptoms and signs is more effective than treatment guided by clinical symptoms and signs alone in patients with HF and left ventricular systolic dysfunction

Inclusion Criteria:

• Female/male, over 18 years with previously verified HF with left ventricular systolic dysfunction.
• New York Heart Association(NYHA) class II-IV,
• NTproBNP males>800 ng/L, females >1000 ng/L

Exclusion Criteria:

• Planned CV hospitalisation, stroke or acute myocardial infarction (MI) last 3 months,
• Mitral/aortic stenosis,
• Patients already receiving optimal HF treatment,
• Severe reduction of kidney function